我們已在上線！進一步了解

Anbio Biotechnology

NNNN

市值 US$1.37億

3.13 USD

-0.17

5.15%

收盤時已更新 10月16日下午4:00 EDT

1天

-5.15%

5天

-32.1%

1個月

-43.91%

3個月

-67.4%

6個月

-88.74%

今年迄今

-89.38%

1年

-88.71%

5年

-45.75%

10年

-45.75%

關於： Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

員工： 27

醫療保健醫療器材與用品

新聞

正面

中性

負面

市場情緒 3個月

正面 100%

中性 0%

負面 0%

Top 3 Health Care Stocks That May Rocket Higher In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That May Rocket Higher In July

Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation

Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers.

Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings

The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahead, although some small deals may list throughout it.

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings

Anbio Biotechnology Announces Closing of Initial Public Offering

Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the provision of in vitro diagnostics products, today announced the closing of its initial public offering (the “Offering”) of 1,600,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of US$5.00 per Class A Ordinary Share. The Class A Ordinary Shares began trading on the Nasdaq Global Market on February 19, 2025 under the ticker symbol “NNNN.”

Anbio Biotechnology Announces Closing of Initial Public Offering

查看新聞排名

價格圖表採用Lightweight Charts™實作